SEVAK AGHAZARYAN: Open Payments
NPI 1104584481 · SUNLAND, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,868 in 112 payments from 20 companies in 2025. Trend: 2023 $1,147 · 2024 $1,822 · 2025 $2,868
Food & beverage: $2,769Education: $99
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 43 | $717 |
| AstraZeneca Pharmaceuticals LP | 13 | $464 |
| Verona Pharma, Inc. | 15 | $366 |
| Merck Sharp & Dohme LLC | 5 | $231 |
| Regeneron Healthcare Solutions, Inc. | 4 | $178 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $144 |
| Lilly USA, LLC | 1 | $120 |
| Insmed, Inc. | 4 | $109 |
| Viatris Specialty LLC | 4 | $100 |
| United Therapeutics Corporation | 3 | $91 |
Products named: NUCALA, Ohtuvayre, TRELEGY ELLIPTA, BREZTRI, WINREVAIR, DUPIXENT, AIRSUPRA, MOUNJARO.
Industry payments across CA — which companies pay providers there.
